top
Search terms
Results 1 - 4 of 4 - ordered by :
Ehjournal

Within 6-month follow-up, the time to AF relapse increased on dronedarone 800mg, with a median of 60 days vs 5.3 days in the placebo group (relative risk reduction 55% [95% CI, 28 to 72%] ...

European Heart Journal, Touboul, Paul, Brugada, Josep, Capucci, Alessandro, Crijns, Harry J.G.M., Edvardsson, Nils, Hohnloser, Stefan H.

Date : 01/08/2003 Item size : 147574 bytes
Ehjournal

Within 6-month follow-up, the time to AF relapse increased on dronedarone 800mg, with a median of 60 days vs 5.3 days in the placebo group (relative risk reduction 55% [95% CI, 28 to 72%] ...

European Heart Journal, Touboul, Paul, Brugada, Josep, Capucci, Alessandro, Crijns, Harry J.G.M., Edvardsson, Nils, Hohnloser, Stefan H.

Date : 01/08/2003 Item size : 147532 bytes
Ehjournal

Methods and results Patients with AF and more than one risk factor for stroke were randomized to one of three blinded doses of betrixaban (40, 60, or 80 mg once daily) or unblinded warfarin, adjusted ...

European Heart Journal, Connolly, Stuart J., Eikelboom, John, Dorian, Paul, Hohnloser, Stefan H., Gretler, Daniel D., Sinha, Uma, Ezekowitz, Michael D.

Date : 21/05/2013
Ehjournal

Within 6-month follow-up, the time to AF relapse increased on dronedarone 800mg, with a median of 60 days vs 5.3 days in the placebo group (relative risk reduction 55% [95% CI, 28 to 72%] ...

European Heart Journal, Touboul, Paul, Brugada, Josep, Capucci, Alessandro, Crijns, Harry J.G.M., Edvardsson, Nils, Hohnloser, Stefan H.

Date : 01/08/2003 Item size : 170622 bytes